ResMed elevates Sandeep Gulati as General Manager, South Asia – ET HealthWorld


ResMed elevates Sandeep Gulati as General Manager, South Asia

Mumbai: ResMed is reinforcing its commitment to India by strengthening its leadership with the appointment of Sandeep Gulati as General Manager, South Asia. In his new role, Sandeep will be responsible for further growth in India market and ensuring that there is increased awareness about sleep and respiratory disorders.

A seasoned and dynamic professional, Gulati brings a rich twenty-three-year-long experience of leading sales and marketing organisations in the pharmaceuticals and medical device industry. Gulati has been a part of ResMed since 2020 and will now lead from the front. In his two years at ResMed as Sales Head – India & South Asia, his long-term vision and strategy led ResMed to achieve strong business results quickly. Sandeep has previously worked in various sales & marketing assignments in Novartis & Baxter for a significant part of his career.

Congratulating Gulati on his new appointment, Carlos Montiel, Vice-President, LATAM & South Asia said, “I welcome Sandeep to his new role. He has very quickly established himself as a strong leader with impeccable business acumen. His analytical approach and consequent strategic thinking has helped achieve great results such as increased reach in marketplace, improved product mix for connected care offerings and alternate opportunities for business growth. He is an innovative, collaborative, and dedicated industry leader who always puts the needs of consumers and fellow ResMedians first along with being an incredible human being. I wish him success with his new responsibilities.”

Expressing gratitude on his appointment, Gulati said, “I am delighted and humbled to be given this responsibility to steer the organisation to fulfil its mission of delivering life-changing, digitally connected health solutions to patients with respiratory issues. India remains a highly undiagnosed market with 29 million individuals affected by obstructive sleep apnoea and all my efforts will continue to be aligned with ResMed’s endeavour to offer out-of-hospital solutions so that more people can be treated. We will remain dedicated to delivering more personalised care, measurable results, and improved health outcomes.”





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *